Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9Y6C2
UPID:
EMIL1_HUMAN
Alternative names:
Elastin microfibril interface-located protein 1
Alternative UPACC:
Q9Y6C2; A0A0C4DFX3; A5PL03; H0Y7A0; Q53SY9; Q96G58; Q96IH6; Q9UG76
Background:
EMILIN-1, also known as Elastin microfibril interface-located protein 1, plays a crucial role in anchoring smooth muscle cells to elastic fibers. It is pivotal not only in the formation of elastic fibers but also in regulating vessel assembly and possesses cell adhesive capabilities.
Therapeutic significance:
The protein is linked to Neuronopathy, distal hereditary motor, 10 (HMN10), a condition characterized by motor neuron degeneration, leading to muscle weakness and gait abnormalities. Understanding EMILIN-1's role could pave the way for novel therapeutic strategies targeting HMN10.